Ximbio, part of Cancer Research UK’s Commercial Partnerships team has partnered with the Institute of Molecular Genetics of the Czech Academy of Sciences. This partnership will make antibodies and other research tools, developed at the Institute of Molecular Genetics of the Czech Academy of Sciences, available to researchers worldwide.
“Recent events have shown the importance of increasing access to resources that accelerate life science research. We are delighted to partner with Ximbio to make our antibodies available worldwide” said Pavel Dráber, a researcher at the Institute of Molecular Genetics of the Czech Academy of Sciences
The antibodies added to Ximbio’s portfolio as a result of this partnership are ideal for use in research areas exploring cell structure and motility. They include monoclonal antibodies that target:
- neurofilament H and M;
- α-, β-, and γ-tubulin;
- Microtubule Associated Proteins 2ab (MAP2ab); and
- Vimentin, transferrin and beta-galactosidase.
Explore these antibodies on Ximbio’s portfolio:
*images taken by E. Dráberová, Laboratory of Biology of Cytoskeleton, IMG
Depicting:
Left: Mouse embryonal fibroblast 3T3. The centrosome is stained with mouse monoclonal antibody TU-31 to g-tubulin (red), microtubules with rabbit polyclonal antibody to a-tubulin (green) and nucleus with DNA binding dye DAPI (blue).
Centre: Mitotic cell of human glioblastoma cell line T98G. Microtubules are stained with mouse monoclonal antibody TU-01 to a-tubulin (green), centrosomes with rabbit polyclonal antibody to g-tubulin (red), chromosomes with DNA-binding dye DAPI (blue).